CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Summary

Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investigators first conducted CD22/CD19 CAR T-cells and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.

Timeline

Start

2020-01-19

Primary completion

2026-07-21

Completion

2039-07-21

Publications

• Qian CS, Wang ZH, Li Z, Yao Z, Gong WJ, Wu YJ, Zhou HX, Xu MZ, Qiu Y, Xu SZ, Tan KW, Liu FT, Huang SM, Cao HY, Dai HP, Wu DP, Xue SL. A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Cancer. 2025 Nov 15;131(22):e70168. doi: 10.1002/cncr.70168.

Drugs

Indications